Press Releases

Press Releases

June 3, 2024
AnHorn Medicines a AI-based drug development platform focused on creating new drugs through protein degradation, has been invited to present its latest research at the NVIDIA AI Summit on June 5 in Taipei, Taiwan.
May 15, 2023
Preclinical data highlights AH-001 as potentially compelling targeted dermatology treatment options.
April 25, 2023
Company’s proprietary drug discovery platform provides unique approach to rationally design bi-functional degraders and molecular glues to have differentiated drug profiles.
July 15, 2022
After 6 months of close collaboration with our AI and drug design teams in discovery, we have advanced the drug profile...
Scroll to Top